Search results
Why CEO AstraZeneca believes the drugmaker can almost double revenue by 2030
CNBC· 9 hours agoAstraZeneca CEO Pascal Soriot explained in a Tuesday interview with CNBC's Jim Cramer why the...
AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock? | The Motley Fool
The Motley Fool· 7 days agoAstraZeneca (AZN -0.70%) is embarking on a fresh business plan that will see it grow significantly...
This Pharma Stock Is Poised to Keep Outperforming the S&P 500
Motley Fool via Yahoo Finance· 6 days agoAstraZeneca has quietly delivered market-beating results since 2014. Despite skepticism, the company...
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
Zacks via Yahoo Finance· 1 day agoAstrazeneca (AZN) closed the most recent trading day at $78.99, moving +1.24% from the previous...
EMA CHMP recommends AstraZeneca’s Tagrisso for lung cancer
Pharmaceutical Technology via Yahoo Finance· 24 hours agoThe Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
Some drugmakers to cap cost of asthma inhalers at $35 a month
NBC News via Yahoo News· 4 days agoStarting Saturday, the cost of inhalers will fall for many Americans, as new out-of-pocket price...
AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
Zacks via Yahoo Finance· 7 days agoAstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival...
AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock
The Motley Fool via AOL· 7 days agoAs two of the world's largest and most prolific drugmakers, Pfizer (NYSE: PFE) and AstraZeneca...
AstraZeneca CEO Has No Plans to Retire as He Seeks to Nearly Double Sales by 2030
The Wall Street Journal· 5 days agoAstraZeneca’s longest-serving chief executive, Pascal Soriot, has no plans to step down for now as...
AstraZeneca started at buy at Goldman, which rates GSK a neutral
Market Watch· 6 days agoGoldman Sachs started coverage of AstraZeneca at buy as it rated rival pharmaceutical company GSK a...